Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 6/20 | 0.55 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.53 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.53 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.53 |
| ▸ | ALK | Q9UM73 | 6/20 | 0.50 |
| ▸ | MET | P08581 | 1/20 | 0.50 |
| ▸ | ROS1 | P08922 | 1/20 | 0.50 |
| ▸ | INSR | P06213 | 4/20 | 0.49 |
| ▸ | CAMK1D | Q8IU85 | 2/20 | 0.47 |
| ▸ | BRD4 | O60885 | 2/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
| ▸ | CTSC | P53634 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1937571 | 0.89 | ALK (0.47) | SYKMAPK8MAPK9MAPK10ALK | |
| SCHEMBL1936571 | 0.86 | ULK1 (0.58) | SYK | |
| SCHEMBL764400 | 0.85 | SYK (0.72) | SYKCAMK1D | |
| SCHEMBL2510547 | 0.82 | CAMK1D (0.47) | SYKALKINSRCAMK1DBRD4 | |
| SCHEMBL1937351 | 0.80 | SYK (0.47) | SYKMAPK8MAPK9MAPK10ALK | |
| SCHEMBL2505875 | 0.78 | SYK (0.41) | SYKMAPK8MAPK9MAPK10ALK | |
| SCHEMBL1937612 | 0.78 | ALK (0.45) | SYKALKINSRBRD4CTSC | |
| SCHEMBL1936513 | 0.77 | FFAR1 (0.47) | SYKMAPK8MAPK9MAPK10CAMK1D | |
| SCHEMBL13363313 | 0.76 | FFAR1 (0.51) | SYKMAPK8MAPK9MAPK10FFAR1 | |
| SCHEMBL2511992 | 0.76 | CTSC (0.52) | SYKALKINSRBRD4CTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110245242-A1 | Heterocyclically Substituted Anilinopyrimides | BAYER CROPSCIENCE AG (DE) | 2011-10-06 | — | — | US | disclosed |
| EP-2331524-A1 | HETEROCYCLICALLY SUBSTITUTED ANILINOPYRIMIDINES AS FUNGICIDES | Bayer CropScience AG (DE) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010025831-A1 | HETEROCYCLICALLY SUBSTITUTED ANILINOPYRIMIDINES AS FUNGICIDES | BAYER CROPSCIENCE AG (DE) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245242-A1 | Heterocyclically Substituted Anilinopyrimides | H1-10, POLL, PPM1D | SYK 1494/4885MAPK8 2444/4885MAPK9 2301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.